Alvotech Wins UK High Court Case, Clears Path for AVT06 Biosimilar Launch

lunes, 10 de noviembre de 2025, 7:46 am ET1 min de lectura
ALVO--

Alvotech has won a legal battle in the UK High Court against Regeneron Pharmaceuticals and Bayer AG, allowing Alvotech to sell its Eylea biosimilar, AVT06, in the UK and European Economic Area. The court rejected the injunction request to block Alvotech's manufacturing of AVT06, paving the way for commercial launches after the expiry date of Supplementary Protection Certificates for Eylea on November 23, 2025. Alvotech shares rose 5.60% to $6.03 in premarket trading.

Alvotech Wins UK High Court Case, Clears Path for AVT06 Biosimilar Launch

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios